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An international research consortium has been formed to facilitate evidence-based intro-
duction of MR-guided radiotherapy (MR-linac) and to address how the MR-linac could 
be used to achieve an optimized radiation treatment approach to improve patients’ 
survival, local, and regional tumor control and quality of life. The present paper describes 
the organizational structure of the clinical part of the MR-linac consortium. Furthermore, 
it elucidates why collaboration on this large project is necessary, and how a central data 
registry program will be implemented.
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cLiNicAL iNtrODUctiON OF Mr-LiNAc AND rAtiONALe
The development of image-guided radiotherapy (IGRT) has driven a paradigm shift in radiation 
oncology. Before the use of IGRT, large margins to correct for geometric uncertainty in space and 
time were required, with significant associated toxicity. Nowadays, a more precise and, for some 
tumor sites, ablative-type treatment approach has become standard of care with the additional goal of 
limiting toxicity and improving the therapeutic index. One of the major developments has been the 
introduction of on-board online cone-beam computed tomography (CBCT) imaging. For example, 
for tumors located in the lungs, this has had a dramatic impact on radiotherapy treatments, as the 
air–tissue interface provides optimal visibility of tumors and allows for a very precise and high-dose 
radiation delivery. This image-guided stereotactic body radiotherapy (SBRT) approach has resulted 
FiGUre 1 | Organizational structure of the clinical working groups in 
the Mr-linac consortium. CSC, Clinical Steering Committee; HCPC, 
Health Care Policy Committee; MAB, Methodology Advisory Board; DMTF, 
Data Management Task Force; TSG, Tumor Site Group.
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in major improvements in radiotherapy control rates and is 
now considered as a treatment option comparable to surgery 
(1). However, CBCT can only be used preceding, not during, 
treatment and does not allow for optimal imaging of tumors and 
organs at-risk when surrounded by soft tissues.
The MR-linac is a hybrid linear accelerator (linac) combined 
with a magnetic resonance imaging (MRI) scanner. As MRI can 
provide optimal soft-tissue contrast, the 1.5-T MR-linac can be 
used for image guidance in multiple sites throughout the body 
providing diagnostic quality images during treatment delivery 
and, therefore, allowing for very accurate image-guided daily 
adaptive radiotherapy. The technology has been described 
previously (2, 3). Among the expected additional benefits of the 
MR-linac compared with existing technologies is hypofraction-
ated dose escalation to the tumor, aiming to increase local control 
rates and survival while having equal or decreased toxicity rates. 
Another approach would be to maintain the conventional dose 
and decrease the risk of toxicity by reducing margins for uncer-
tainty and tumor motion, as the system allows for daily fast adap-
tive replanning and gated or tracked radiotherapy treatments. 
Furthermore, functional imaging may allow for adaptive focal 
boosting and personalized inhomogeneous target dosage based 
on response.
The first technical prototype MR-linac has been developed 
and installed in UMC Utrecht. Since 2008, it has been used 
to develop, evaluate, and validate clinical procedures, in col-
laboration with Elekta and Philips. In 2012, an international 
consortium (MR-linac Consortium) was formed, which 
will collaboratively implement the clinical introduction of 
the MR-linac. The MR-linac Consortium members include 
the University Medical Center Utrecht, The Netherlands; 
Netherlands Cancer Institute – Antoni van Leeuwenhoek 
Hospital, The Netherlands; The Institute of Cancer Research/
The Royal Marsden Hospital, UK; The Christie NHS 
Foundation Trust/Manchester Cancer Research Centre, UK; 
The University of Texas MD Anderson Cancer Center, USA; 
The Froedtert & Medical College Wisconsin, USA; Sunnybrook 
Odette Cancer Center, Canada; Elekta AB, Sweden and Philips, 
The Netherlands. All consortium institutes will install clinical 
prototypes of the MR-linac. The first clinical prototypes have 
been installed at the UMC Utrecht and MD Anderson and are 
currently being commissioned and used to validate clinical 
procedures. Installation is planned for the other collaborating 
institutes in 2016. The research consortium has access to the 
developing MR-linac technology, for which extended technical 
specifications will be available at each clinical update (including 
the possibility of functional imaging).
The goal of the present paper is to describe the organization 
of the MR-linac research consortium (Figure 1). The described 
structure may be adapted for implementation and evaluation of 
future technologies.
cOLLABOrAtiON iN Mr-LiNAc 
cONsOrtiUM
Collaboration is essential for success in improving outcomes 
of radiation treatments when introducing an innovative and 
complex technology. The key role of the research consortium 
is to design studies and the data registry system in such a way 
that evidence will be gathered for maximizing and proving the 
clinical benefit of the MR-linac. This ambitious project aims to 
create a paradigm shift in radiation oncology to improve clinical 
outcomes. Therefore, the project is heavily dependent on the 
collaboration of the institutes. To achieve this, the consortium’s 
success is put first, rather than the interests of individuals. Having 
a consortium allows for mentorship of junior faculty by experi-
enced senior faculty and will allow junior faculty to expand their 
knowledge and competencies. The multi-institutional studies 
performed within the consortium will allow for faster accrual of 
patients and larger patient numbers, thus providing evidence of 
the clinical benefit of the technology in a coordinated and more 
timely manner. In addition, the approval by regulatory bodies 
(CE, FDA, ethical committee) will be more straightforward 
and faster, and grant applications for national and international 
funding for clinical studies will be facilitated. Clinical working 
groups (WGs) will address and develop tumor site-specific 
MR-procedures and sequences, feasibility and efficacy studies 
(Figure 2). Pretreatment anonymized data and quality assurance 
(QA) data will be developed together and shared, shortening the 
time toward clinical implementation. By developing consortium-
wide imaging protocols, consensus MR-based contouring 
atlases, dose prescription definitions and dose constraints, 
toxicity, quality of life (QoL) and patient-reported outcome 
measures (PROMS) scoring systems, and treatment registration 
parameters, the MR-linac will achieve consistency in radiation 
treatment and establish standards on quality. With all consor-
tium members using standard, predefined survival parameters, 
criteria for tumor response and disease recurrence, toxicity 
FiGUre 2 | timeline of clinical studies within the Mr-linac consortium. Installation of MR-linacs at all consortium institutes are either ongoing or planned for 
2016. Regulatory approval for the integrated MR-linac system is planned for 2017.
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criteria, and PROMS, multi-institutional clinical research into 
the effectiveness of the MR-linac will be easier and of higher 
quality. Trial approval processes may be time consuming, with 
associated costs and delay adoption. Submitting study proposals 
in a more structured way for multiple tumor sites at one time, 
i.e., an “umbrella” proposal, for Ethical Committee review, will 
facilitate an efficient and more straightforward approval process. 
Disadvantages of having a large research consortium including 
>100 radiation oncologists and >200 physicists, technologists, 
engineers, dosimetrists, radiation therapists, researchers, epide-
miologists, and statisticians, are that communication requires an 
effective coordination including infrastructure, roles and respon-
sibilities of the individuals involved. The number of consortium 
partners may increase the risk of slowing the trajectory from idea 
to clinical implementation and may impact the decision-making 
process. Furthermore, there are obviously costs associated with 
such a large organization, in terms of personnel, infrastructure, 
and meetings.
OrGANiZAtiONAL strUctUre  
Mr-LiNAc cONsOrtiUM
The consortium consists of technical and clinical WGs, which 
interact on a regular basis during group-specific meetings, con-
sortium meetings, consortium-wide teleconferences, institute-
specific meetings, and interval meetings via the coordinators of 
the WGs. The present manuscript will focus on the organization 
of the clinical WGs of the MR-linac consortium. The technical 
WGs are outside the scope of this paper, although extensively 
collaborating. An alternative organizational structure would have 
been to have a natural formation of clinical groups, although this 
would have resulted in a slower formation of groups, a larger 
number of tumor sites, risking delays in demonstrating clinical 
benefit.
clinical steering committee
The goal of the Clinical Steering Committee (CSC) is to stimulate 
and guide collaboration. The CSC discusses high-level aspects 
of clinical research, including study design, data management, 
organization, and collaboration. Individual members are 
responsible for communication within their respective institu-
tions. Furthermore, the CSC has organized the development of 
the clinical WGs and has been involved in the selection of the 
first tumor sites for consortium-wide studies. After site-visits 
and meetings with department heads, clinicians, physicists, and 
industry, the CSC has been convened. The CSC has formed the 
clinical WGs, including anticipated participants, coordinators, 
roles, responsibilities, organizational structure, and communica-
tion pathways of the consortium. The CSC serves a key role in 
data oversight. The CSC will work closely with the other clinical 
groups to ensure that there is adherence to the collaboration 
agreements as well as to evaluate whether existing guidelines 
and agreements are relevant. Lastly, the CSC will manage data 
ownership, publication rights, and data release. As the decisions 
made by the CSC relate to department leadership decisions, the 
members are heads of their Radiation Oncology departments or 
act on behalf of the department heads. Any formal collaboration 
agreements are signed by the institute’s leadership.
tumor site Groups
There are many clinical indications where the MR-linac may 
have an expected benefit (a consortium-wide questionnaire 
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resulted in 25 candidate indications). When introducing a 
new technology in radiation oncology, it is important that the 
number of indications is not too high in the initial phases, 
since this can reduce the quality of research and delay clini-
cal adoption. Therefore, nine tumor sites have been selected 
in which to start the consortium-wide clinical studies. This 
selection was based on the expected clinical benefits by the 
key opinion leaders (either increased local control or survival, 
or decreased toxicity, or improved QoL), potential patient 
numbers (average incidence per year) at the collaborating 
institutes, and the (tumor site specific) research expertise of 
the collaborating centers. The first tumor sites are a starting 
point and are intended not to exclude subsequent studies for 
other clinical indications. These nine consortium-wide tumor 
sites are brain, breast, cervix, esophagus, lung, oropharynx, 
pancreas, prostate, and rectum. Each institute coordinates one 
or more Tumor Site Groups (TSGs). The TSGs are chaired by 
a Disease Site Coordinator (DSC). The DSC facilitates trials on 
a tumor site, organizes, and supports the TSG, helps identify 
and secure adequate funding, and communicates with other 
clinical and technical WGs in the consortium. In each TSG, 
one physician participates from each institute, as well as physi-
cists. The roles of the TSG are to discuss and prepare predicate 
clinical study proposals for MRI studies (i.e., MR-sequence 
optimization for radiotherapy, MR-based planning study, 
MR-based contouring study, and development of consensus 
delineation atlases), to prepare joint clinical study proposals 
for feasibility and future randomized controlled trials. The 
TSG also communicates with other WGs on the necessary 
technical specifications and anticipated timelines. As recom-
mended by the Accelerated Access Review (aiming to acceler-
ate access to innovations for NHS patients in the UK), patients 
should be involved in every step of the innovation pathway (4). 
Patients will be involved in the clinical trial development and 
evaluation for each disease site, leading to implementation of 
innovative treatments focusing on treatment outcomes that are 
most important to patients.
Health care Policy committee
The HCPC will develop a comprehensive strategic plan to 
ensure patient access and reimbursement by communicating 
the value of treatment with the MR-linac by disease site to the 
appropriate agencies and stakeholders. The HCPC focuses on 
the MR-linac overall cost effectiveness for patients, health care 
providers, and funding bodies. The HCPC will work closely with 
the CSC and TSG to ensure that publications of the disease-site 
specific data are communicated in a timely manner. Gathering 
clinical evidence to establish the value of the treatment with the 
MR-linac (which will result from the efforts of the TSGs) will be 
a necessary step toward reimbursement. The WG activities will 
involve members of the consortium, patients, industry, medical 
societies, government, and managed care. The HCPC will evalu-
ate the health care policies toward advanced technologies and 
the MR-linac by local governments, managed care, and medical 
societies.
Data Management task Force
All patients treated on the MR-linac by the Consortium members 
will be registered in a consortium-wide data registry and all 
clinical trials will be registered prospectively. Currently, most 
patients treated by radiotherapy are not enrolled in clinical 
trials. Furthermore, inefficient data management is a concern, 
as this may lead to loss of a significant amount of research data. 
The data registry ensures accurate and comprehensive data 
collection for evaluating and modeling treatment outcomes, 
radiomics, QA, and technological improvements. In addition, 
the joint data registry connects the institutes, strengthens their 
commitment to collaboration and will enhance transparency 
in the conduct and reporting of clinical trials. The clinical 
institutes of the consortium will have access to de-identified 
data and all anonymized clinical data. The data management 
WG “core team” is the DMTF, which has representatives from 
all institutes. In addition, three sub-teams have been installed; 
legal, IT, and medical/data in accordance with the guidelines by 
Skripcak et  al. (5). The DMTF has prepared a model for data 
management, which has been approved by the CSC. The DMTF 
will propose the strategy, together with the required governance 
agreement to the institutes’ leadership, for final approval. After 
approval, the data registry will be implemented and tested at 
all institutes, before official release together with the associated 
documentation. The legal team will address aspects, such as 
privacy, governance documentation, data ownership, and will 
advise on the “umbrella” Ethical Committee protocol submis-
sion, as required prior to the start of inclusion of patients in 
the consortium-wide data registry. The IT team is developing 
the data registry system and methods to retrieve data from the 
various electronic hospital information systems and protected 
data storage. The data-team focuses on the classes of data to be 
collected, such as clinical information and tumor characteristics, 
imaging data, treatment plan data, machine treatment data, 
treatment outcomes (tumor control, survival, toxicity, PROMS). 
Each institute will appoint dedicated data managers to facilitate 
consortium-wide data collection.
Methodology Advisory Board and the 
r-iDeAL Framework
The Methodology Advisory Board (MAB) advises on study 
design of MR-linac technology within clinical studies, aiming for 
evidence-based introduction of the technology. Past experiences 
have shown that the window of opportunity for appropriate 
evaluation of innovations in radiation oncology is narrow: dif-
ferences in perception of equipoise and pressure from patients, 
doctors, and industry have led to implementation of innovations 
without robust clinical evidence of superiority. The MR-linac 
technology is complex, allows for numerous treatment strate-
gies, and continuous technical improvements. As evaluation of 
complex interventions is challenging, the MAB has proposed to 
implement an adapted version of the IDEAL recommendations 
for evaluation of MR-linac (6), the IDEAL framework was origi-
nally developed for evaluation of surgical innovations and aims 
to prevent delay in the introduction of promising interventions 
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without exposing patients to unnecessary risks and toxicity. 
IDEAL consists of five stages: an Idea or Innovation, which then 
undergoes Development and Exploration, and subsequently 
Assessment and Long-term studies. At each stage, the IDEAL 
framework includes recommendations for methodology and 
reporting. For radiotherapy innovations, we have added a stage 
0 (radiotherapy predicate studies), covering all the work that is 
performed before the innovation is used for treating patients 
(such as delineation studies, optimization of MRI sequencing 
protocols – for instance, MRI sequence optimization for radio-
therapy, MR-based planning study, planning study in the pres-
ence of 1.5T magnetic field, MR-only planning – and modeling 
studies to identify disease sites/indications where the MR-linac 
is expected to be of greatest benefit). For each tumor site and 
indication, for which, the MR-linac will be used, all stages need 
to be considered. After each stage, an assessment will take place 
in which it is decided whether the technique is ready to be taken 
to the next stage or whether previous steps need to be repeated. 
By recommending all TSGs to follow the R-IDEAL framework 
and to report results after each stage, we guarantee a high-quality, 
systematic, and uniform approach to evaluation and provide 
the opportunity for TSGs to learn from each other. The MAB 
interacts closely with the TSGs to advise on optimal study design 
at the different stages and gives feedback from study experiences 
from other groups.
iNterDisciPLiNArY cOLLABOrAtiON 
AND tecHNicAL WOrKiNG GrOUPs iN 
tHe Mr-LiNAc cONsOrtiUM
The quality of patient care in radiotherapy relies heavily on the 
teamwork of all members of the radiation oncology department. 
The team includes radiation oncologists, radiation physicists, 
dosimetrists, radiation therapists, nurses, support staff members, 
and clerical staff members. For the MR-linac project, there are 
additional interdisciplinary and international collaborations 
that will be essential if we are to accomplish safe and effective 
radiation treatment on this new platform. These individuals 
include technicians/radiographers, researchers, industry, IT, data 
managers, and members of the clinical and technical MR-linac 
Consortium WGs.
The uniqueness of the consortium lies in the early involvement 
of institutes in the development process of this innovative tech-
nology. The focus of industry is not only on solving engineering 
problems but also a long-term strategy for the route to adoption of 
the technology. This can only be achieved through generation of 
clinical evidence. When clinical members are not involved early, 
this results in adoption problems by the clinical community later, 
commonly at the phase where the community requires evidence 
a few years after the technology has been introduced. The advan-
tage of the early collaboration of academia with industry is that 
working together on technology development and optimization 
ensures a more rapid availability of technical specifications to the 
institutes. In addition, the clinical members’ advise the developers 
on which specifications are required to optimally improve clinical 
outcomes for patients. This early collaboration does come with 
the potential risk of introduction of bias in the clinical results. 
To mitigate this risk and in order to maintain scientific integrity, 
the scientific evaluation of the clinical benefit of the technology 
will be done by the institutes themselves and will be independent 
from industry.
The four TWGs (i.e., QA, MRI, Adaptive Elements, and 
Workflow) are beyond the scope of the present clinical perspec-
tive paper. However, these groups collaborate closely with the 
clinical groups and interact on a regular basis and will therefore be 
described briefly below. In the TWGs, members from the industry 
and all institutes are collaborating. The QA group is responsible 
to implement a QA protocol following a Failure Mode Effect 
Analysis (FMEA) risk based approach. Subjects, such as reference 
dosimetry, offline and real-time QA, End2End QA, Patient QA, 
and MRI-QA, are reviewed and modified to ensure an optimal 
dosimetric and geometric accuracy of the entire system. The MRI 
group works on the optimization of MRI protocols, development 
of MR sequences, and MRI QA, including geometric accuracy. 
In the Adaptive Elements group, fast adaptive replanning, gat-
ing, and tracking solutions are developed. The Workflow group 
handles the technology-user interface, ensuring that the system 
is designed to support an efficient and effective clinical workflow 
for treatment of patients.
In summary, we report the development of a consortium based 
research group to help facilitate the design, implementation, 
and management of clinical research in MR-linac technology. 
The consortium provides a shared governance model, which is 
unique among academic centers. It engages broad membership 
and provides a clinical development plan to address outcomes 
and value of a new technology. The early involvement of institutes 
in the development process of the technology should increase the 
chance for success of this innovative technology.
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